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Abstract
Congenital myasthenic syndromes (CMS) are a clinically and genetically heterogeneous group of disorders caused by
mutations which lead to impaired neuromuscular transmission. SLC25A1 encodes a mitochondrial citrate carrier, associated
mainly with the severe neurometabolic disease combined D-2- and L-2-hydroxyglutaric aciduria (D/L-2-HGA). We previously
reported a single family with a homozygous missense variant in SLC25A1 with a phenotype restricted to relatively mild CMS
with intellectual disability, but to date no additional cases of this CMS subtype had been reported. Here, we performed whole
exome sequencing (WES) in three additional and unrelated families presenting with CMS and mild intellectual disability to
identify the underlying causative gene. The WES analysis revealed the presence of a homozygous c.740G>A; p.(Arg247Gln)
missense SLC25A1 variant, the same SLC25A1 variant as identified in the original family with this phenotype. Electron
microscopy of muscle from two cases revealed enlarged and accumulated mitochondria. Haplotype analysis performed in two
unrelated families suggested that this variant is a result of recurrent mutation and not a founder effect. This suggests that p.
(Arg247Gln) is associated with a relatively mild CMS phenotype with subtle mitochondrial abnormalities, while other variants
in this gene cause more severe neurometabolic disease. In conclusion, the p.(Arg247Gln) SLC25A1 variant should be
considered in patients presenting with a presynaptic CMS phenotype, particularly with accompanying intellectual disability.
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Introduction
Congenital myasthenic syndromes (CMS) are a hetero-
geneous group of disorders caused by mutations leading to
impairment of neuromuscular transmission. Most often,
these disorders arise from mutations affecting postsynaptic
components of the neuromuscular junction (NMJ). CMS
due to mutations affecting the motor nerve terminal com-
prise a rarer subset; they are however, increasingly recog-
nised, and the majority of the recently discovered CMS
genes result in presynaptic NMJ defects [1].
SLC25A1 is a mitochondrial citrate carrier which med-
iates the exchange of citrate/isocitrate with cytosolic malate
[2]. Variants in the SLC25A1 gene are associated with
severe neurometabolic disease [3–5]. We previously iden-
tified a homozygous c.740G>A; p.(Arg247Gln) missense
variant in SLC25A1 in a British sib-pair presenting with a
mild form of CMS with intellectual disability [6]. Here we
report three additional unrelated CMS families carrying the
same missense variant in SLC25A1, presenting with
a similar phenotype, confirming the genotype–phenotype
association.
Materials and methods
Patients
Patients were identified and fully investigated with standard
clinical, electrophysiological and myopathological exam-
inations at specialised neurology and neuromuscular clinics,
namely Department of Neurology, National Institute of
Mental Health and Neuroscience, India, Department of
Neuropediatrics and Muscle Disorders, Freiburg University,
Germany and the NHS Highly Specialised Mitochondrial
disease service, Newcastle Upon Tyne hospitals NHS
Foundation Trust, UK. Written consent was obtained for all
participants to publish their clinical photographs. DNA
samples were submitted to the Newcastle MRC Centre
Biobank for Neuromuscular Diseases for which ethical
approval was granted by the NRES Committee North East
—Newcastle & North Tyneside 1 (reference 08/H0906/28).
We have conducted the research in accordance with the
Declaration of Helsinki.
Whole exome analysis (WES) and Haplotype analysis
WES was performed by the Genomics Platform at the Broad
Institute of MIT and Harvard, Cambridge, USA. Libraries
were created with an Illumina exome capture (38Mb target)
and sequenced with a mean target coverage of >80×.
Exome data was then processed at the Centro Nacional de
Análisis Genómico (CNAG), Barcelona, Spain, and variant
prioritization was carried out on the Genome–Phenome
Analysis Platform. Standard filtering criteria were applied,
including minor allele frequency of 1% and high to moderate
effect on protein structure (i.e. nonsense, splice site, frame
shift, in-frame and non-synonymous variants), and using a
gene list of 416 genes known to be associated with neuro-
muscular disease. The identified SLC25A1 variant has been
submitted to ClinVar ((https://www.ncbi.nlm.nih.gov/clinvar/
) under accession number: SCV000853306.1). Genomic data
for patients 1/1, 2/1 and 2/2 were analysed for runs of
homozygosity (RoH) using PLINK (http://zzz.bwh.harvard.
edu/plink/ibdibs.shtml) and the respective haplotypes were
identified manually.
Results
Clinical description
We identified six patients from four families of different
ethnicity (British, Indian, Greek and Pakistani) (Table 1 and
Fig. 1). Three families were consanguineous. All patients
developed a non-progressive proximal weakness in early
infancy, which fluctuated with physical activity and was
clearly fatigable on examination. Some degree of involve-
ment of extraocular muscles was found in all patients,
which ranged from severe bilateral ptosis (Fig. 1c, patient 3/
1) to subjective diplopia only (patient 1/2). Respiratory
function was normal in all cases. In addition, all patients
had mild intellectual disability. No symptoms of autonomic
dysfunction were reported by any of the patients. MRI brain
was performed in four cases and was normal in all. Serum
lactate was normal at rest in all, but in two cases showed
increase after exercise. Two patients had functional benefit
from acetylcholinesterase (AChE) inhibitor treatment, but in
other cases it was not beneficial despite adequate dosing.
One case was treated with 3, 4-diaminopyridine and
responded well to the treatment, in-keeping with a pre-
synaptic NMJ defect (Table 1).
Repetitive nerve stimulation (RNS) showed decrement
in two patients at 3 Hz stimulation, and significantly
increased jitter on single fibre electromyography in five
patients.
Muscle biopsy was performed in three cases and showed
non-specific myopathic features in all. In addition, on
electron microscopy two cases showed enlarged and accu-
mulated mitochondria.
Genetic analysis
After WES variant filtering, the same homozygous
missense variant hg19 chr22:g.19164098C>T; c.740G>A;
p.(Arg247Gln) in SLC25A1 (GenBank NM_005984.5) was
374 S. Balaraju et al.
Ta
bl
e
S
um
m
ar
y
of
th
e
cl
in
ic
al
,
ne
ur
op
hy
si
ol
og
ic
al
an
d
bi
oc
he
m
ic
al
fe
at
ur
es
of
th
e
ca
se
s
P
re
vi
ou
s
st
ud
y
C
ur
re
nt
st
ud
y
F
am
ily
/p
at
ie
nt
/a
ge
at
ex
am
/s
ex
1/
1/
37
/M
1/
2/
23
/F
2/
1/
26
/M
2/
2/
25
/F
3/
1/
14
/M
4/
1/
14
/F
E
th
ni
c
or
ig
in
B
ri
tis
h
B
ri
tis
h
In
di
an
In
di
an
G
re
ek
P
om
ak
P
ak
is
ta
ni
C
on
sa
ng
ui
ni
ty
Y
es
Y
es
Y
es
Y
es
N
o
Y
es
A
ge
of
on
se
t
In
fa
nc
y
In
fa
nc
y
In
fa
nc
y
In
fa
nc
y
In
fa
nc
y
In
fa
nc
y
C
M
S
-a
ss
oc
ia
te
d
fe
at
ur
es
O
cu
la
r
in
vo
lv
em
en
t
M
ild
bi
la
te
ra
l
pt
os
is
,
no
op
ht
ha
l
D
ip
lo
pi
a,
no
pt
os
is
M
ild
op
ht
ha
l
an
d
pt
os
is
M
ild
op
ht
ha
l
an
d
pt
os
is
M
ar
ke
d
pt
os
is
,
m
ild
op
ht
ha
l
M
ild
pt
os
is
,
di
pl
op
ia
B
ul
ba
r
in
vo
lv
em
en
t
Y
es
N
o
N
o
N
o
Y
es
Y
es
W
ea
kn
es
s
di
st
ri
bu
tio
n
P
ro
xi
m
al
,
U
L
=
L
L
P
ro
xi
m
al
,
U
L
=
L
L
,
N
F
w
ea
kn
es
s
P
ro
xi
m
al
,
U
L
=
L
L
P
ro
xi
m
al
,
U
L
=
L
L
P
ro
xi
m
al
,
U
L
=
L
L
P
ro
xi
m
al
,
L
L
>
U
L
,
N
F
w
ea
kn
es
s
F
at
ig
ab
ili
ty
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
T
re
at
m
en
t;
re
sp
on
se
A
C
hE
I—
no
re
sp
on
se
;
3,
4-
D
A
P
—
go
od
re
sp
on
se
A
C
hE
I—
so
m
e
re
sp
on
se
A
C
hE
I
an
d
sa
lb
ut
am
ol
—
no
re
sp
on
se
A
C
hE
I
an
d
sa
lb
ut
am
ol
—
no
re
sp
on
se
A
C
hE
I—
so
m
e
re
sp
on
se
A
C
hE
I—
no
re
sp
on
se
A
dd
iti
on
al
cl
in
ic
al
fe
at
ur
es
In
te
lle
ct
ua
l
di
sa
bi
lit
y
M
ild
,a
tte
nd
ed
m
ai
ns
tr
ea
m
sc
ho
ol
Y
es
,
at
te
nd
ed
sc
ho
ol
w
ith
ad
di
tio
na
l
su
pp
or
t
ne
ed
s
U
na
bl
e
to
re
ad
/w
ri
te
/
ca
lc
ul
at
e
B
in
et
-K
am
at
IQ
sc
or
e:
45
U
na
bl
e
to
re
ad
/w
ri
te
Y
es
,a
tte
nd
ed
sc
ho
ol
w
ith
ad
di
tio
na
l
su
pp
or
t
ne
ed
s
M
ild
,
at
te
nd
ed
m
ai
ns
tr
ea
m
sc
ho
ol
D
ys
m
or
ph
is
m
N
o
N
o
E
lo
ng
at
ed
fa
ci
es
,
pr
om
in
en
t
ea
rs
,
hi
gh
ar
ch
ed
pa
la
te
E
lo
ng
at
ed
fa
ci
es
,
pr
om
in
en
t
ea
rs
N
o
N
o
O
th
er
P
es
ca
vu
s
B
ic
us
pi
d
A
V
an
d
M
V
pr
ol
ap
se
H
yp
er
m
ob
ili
ty
,
in
cr
ea
se
in
la
ct
at
e
w
ith
ex
er
ci
se
H
yp
er
ex
te
ns
ib
le
jo
in
ts
,
ch
in
fa
sc
ic
ul
at
io
ns
P
es
pl
an
ov
al
gu
s
W
ea
kn
es
s
ex
ac
er
ba
te
d
by
he
at
an
d
co
ld
.
M
ar
ke
d
in
cr
ea
se
in
la
ct
at
e
w
ith
ex
er
ci
se
N
eu
ro
ph
ys
io
lo
gy
R
ep
et
iti
ve
ne
rv
e
st
im
ul
at
io
n
N
o
de
c
on
3
H
z
st
im
ul
at
io
n,
no
in
c
af
te
r
20
s
M
V
C
N
ot
do
ne
D
ec
re
m
en
t
on
3
H
z
st
im
ul
at
io
n
(M
V
C
no
t
pe
rf
or
m
ed
)
D
ec
re
m
en
t
on
3
H
z
st
im
ul
at
io
n
(M
V
C
no
t
pe
rf
or
m
ed
)
N
o
de
c
on
3
H
z
st
im
ul
at
io
n,
no
in
c
af
te
r
20
s
M
V
C
N
o
de
c
on
3
H
z
st
im
ul
at
io
n
(M
V
C
no
t
pe
rf
or
m
ed
)
S
in
gl
e
fi
br
e
E
M
G
In
cr
ea
se
d
jit
te
r
an
d
bl
oc
k
N
ot
do
ne
N
ot
do
ne
N
ot
do
ne
N
ot
do
ne
Ji
tte
r
w
ith
in
no
rm
al
lim
its
A
dd
iti
on
al
an
al
ys
is
M
us
cl
e
bi
op
sy
N
or
m
al
C
O
X
st
ai
ni
ng
,
en
la
rg
ed
m
ito
ch
on
dr
ia
an
d
in
cr
ea
se
d
in
nu
m
be
r
on
E
M
N
ot
do
ne
N
ot
do
ne
N
ot
do
ne
F
ib
re
si
ze
va
ri
at
io
n,
fe
w
ce
nt
ra
l
co
re
s;
sp
or
ad
ic
al
ly
ac
cu
m
ul
at
ed
m
ito
ch
on
dr
ia
in
E
M
M
ild
ly
at
ro
ph
ic
fi
br
es
,
no
rm
al
C
O
X
st
ai
ni
ng
,
m
ild
re
du
ct
io
n
in
co
m
pl
ex
1
ac
tiv
ity
U
ri
ne
2-
hy
dr
ox
yg
lu
ta
ra
te
N
or
m
al
N
or
m
al
N
ot
do
ne
N
ot
do
ne
N
or
m
al
N
ot
do
ne
M
R
I
br
ai
n
N
or
m
al
N
or
m
al
N
ot
pe
rf
or
m
ed
N
or
m
al
N
ot
pe
rf
or
m
ed
N
or
m
al
3,
4-
D
A
P
3,
4-
di
am
in
op
yr
id
in
e,
A
C
hE
I
ac
et
yl
ch
ol
in
es
te
ra
se
in
hi
bi
to
r,
C
O
X
cy
to
ch
ro
m
e
c
ox
id
as
e,
D
ec
de
cr
em
en
t
of
co
m
po
un
d
m
us
cl
e
ac
tio
n
po
te
nt
ia
l,
E
M
el
ec
tr
on
m
ic
ro
sc
op
y,
E
M
G
el
ec
tr
om
yo
gr
ap
hy
,
In
c
in
cr
em
en
t
of
co
m
po
un
d
m
us
cl
e
ac
tio
n
po
te
nt
ia
l,
L
L
lo
w
er
lim
b,
M
V
C
m
ax
im
um
vo
lu
nt
ar
y
co
nt
ra
ct
io
n,
N
F
ne
ck
fl
ex
or
w
ea
kn
es
s,
O
ph
th
al
op
ht
ha
lm
op
le
gi
a,
R
N
S
re
pe
tit
iv
e
ne
rv
e
st
im
ul
at
io
n,
U
L
lo
w
er
lim
b
Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant 375
identified in all patients. Sequencing data for patients 1/1
(British origin), 2/1 and 2/2 (Indian origin) were analysed to
identify possible RoH around the SLC25A1 variant. As
expected due to their consanguinity, patients 2/1 and 2/
2 shared a large RoH of 1.43Mb (from chr22:18870865 to
20325552), whereas patient 1/1 had a much smaller RoH of
0.15Mb (from chr22:19148244 to 19299703). The geno-
types within the shared region between the two families
differ in at least five homozygous calls (i.e. hg38 chr22:
g.19177322A>C; rs3213491, hg38 chr22:g.19199939G>A;
rs2236760, hg38 chr22:g.19199940C>G; rs2236761, hg38
chr22:g.19208992G>A; rs1060376 and hg38 chr22:
g.19258298A>G; rs3788295), suggesting that they repre-
sent two distinct haplotypes.
Discussion
Pathogenic variants in SLC25A1 cause combined D-2- and
L-2-hydroxyglutaric aciduria (D/L-2-HGA), a severe
metabolic neurodevelopmental disorder with early lethality
[3–5]. We previously reported that the homozygous p.
(Arg247Gln) missense variant caused a CMS phenotype but
without systemic manifestations of a mitochondrial disease
[6]. Here, we report three additional CMS families of dif-
ferent ethnicity harbouring the same homozygous missense
variant. Interestingly, the haplotype of the Indian and
British families [6] were distinct, suggesting this variant is
not seen as a result of a founder effect but rather to recurrent
mutation.
Clinically these families had early onset, fatigable ocular,
bulbar and proximal muscle weakness, which are clinical
hallmarks of impaired neuromuscular transmission. In
addition, cognitive impairment was found in all cases.
Several presynaptic CMS genes including SNAP25B [7],
MUNC13 [8],MYO9A [9], SLC18A3 [10] and SLC5A7 [11],
as well as mutations in DPAGT1 [12], are known to be
associated with cognitive and behavioural problems, which
may reflect the importance of these genes in central as well
as peripheral synapses. Our findings suggest that SLC25A1
and in particular the p.(Arg247Gln) variant should also be
considered in CMS cases with intellectual disability.
Ptosis, ophthalmoplegia and fatigable muscle weakness
can also occur in mitochondrial disease along with many
other severe systemic symptoms [13]. Unlike the typical
clinical progression in mitochondrial disorders, the muscle
weakness in our cohort was non-progressive. Pathogenic
variants in SLC25A1 which cause D/L-2-HGA are typically
in amino acid residues which are crucial for protein activity,
whereas the variant documented here was shown to result in
reduced carrier activity with compensatory increase in
protein expression [6, 14]. Consistent with this, all patients
were found to have normal urinary 2-HG levels. In addition,
muscle biopsy showed subtle mitochondrial abnormalities
on electron microscopy, but normal or only mildly reduced
mitochondrial oxidative enzyme reactivities in-keeping with
a mild mitochondrial defect.
In previous studies, we showed that SLC25A1 defi-
ciency results in a primary presynaptic defect [6]. Mito-
chondria play important roles in the presynaptic nerve
terminal, which is a site of high energy requirement [15]. In
particular, mitochondria are involved in the regulation of
presynaptic calcium [16]. Lambert Eaton Myasthenic
Syndrome (LEMS) is caused by antibodies against the
presynaptic voltage gated calcium channel. Another CMS
phenotype overlapping with LEMS, which results in
impaired presynaptic calcium signalling, has been descri-
bed recently [17]. This includes increment on RNS after a
period of maximum voluntary contraction, and response to
3,4-diaminopyridine (3,4-DAP), a presynaptic potassium
channel blocker. However, none of the patients in this
cohort exhibited features in-keeping with LEMS on neu-
rophysiological tests. 3,4-DAP resulted in good clinical
benefit in one case, but has not been trialled in other cases.
In summary, the p.(Arg247Gln) SLC25A1 variant
should be considered in patients presenting with a pre-
synaptic CMS, particularly with accompanying intellec-
tual disability.
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